Company: NDRA
Filing Date: 2025-04-07
Form Type: 10-K/A
Source: 0001654954-25-003937
Chunk: 28

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-04-07
Form: 10-K/A
Chunk 28
---
 those described in the summary of significant accounting policies. The CODM assesses performance for the biotech segment based on net loss, which is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets.

To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.

As such, the CODM uses cash forecast models in deciding how to invest into the biotech segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.

| F-18 |

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:

|                                   |     |   Year Ended |             |   |     |   Year Ended |             |   |
|:----------------------------------|:----|-------------:|------------:|:--|:----|-------------:|------------:|:--|
|                                   |     | December 31, |             |   |     | December 31, |             |   |
|                                   |     |         2024 |             |   |     |         2023 |             |   |
| Operating Expenses                |     |              |             |   |     |              |             |   |
| Research and development          |     |            $ |   3,190,293 |   |     |            $ |   5,003,695 |   |
| Sales and marketing               |     |              |     571,040 |   |     |              |     820,554 |   |
| General and administrative        |     |              |   7,055,814 |   |     |              |   4,696,486 |   |
| Total operating expenses          |     |              |  10,817,147 |   |     |              |  10,520,735 |   |
| Operating loss                    |     |              | (10,817,147 | ) |     |              | (10,520,735 | ) |
| Other segment items (a)           |